Alembic Pharmaceuticals has informed that the Company’s API Facilities i.e. API I and API II both located at Panelav have been successfully inspected by the USFDA between June 20, 2016 and June 29, 2016. The Company did not receive any Form 483 observations.
The above information is a part of company’s filings submitted to BSE.